Krystal Biotech (KRYS) Stock: Buy, Sell, or Hold?
KRYS - Krystal Biotech, Inc. Common Stock
$320.13
-2.04 (-0.63%)
▼
5d:
-2.99%
30d:
-6.33%
90d:
-4.49%
BUY
HIGH Confidence
Analysis Updated: Oct 22, 2026 12:00 AM ET
Earnings: Nov 02, 2026
9d
Get Alerted When KRYS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: KRYS shows strong fundamentals and good volume confirmation. Solid entry point despite oversold pricing.
✅ BUY SIGNAL: KRYS shows strong fundamentals and good volume confirmation. Solid entry point despite oversold pricing.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$375.26
Based on 11.0% avg growth
INTRINSIC VALUE TODAY
$233.00
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: KRYS is currently trading at $320.13, which is considered oversold relative to its 30-day fair value range of $323.37 to $340.21. From a valuation perspective, the stock is trading at a premium (Forward PE: 35.8) compared to its historical average (31.1). At these levels, the market is pricing in 4.8% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, KRYS is showing sideways momentum. The price is currently testing key support at $314.22. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: KRYS scores 81/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $395.44 (+23.5%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, KRYS is showing sideways momentum. The price is currently testing key support at $314.22. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: KRYS scores 81/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $395.44 (+23.5%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$323.37 -
$340.21
Company Quality Score
64/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
93.1%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Options cheap (IV 0th percentile)
- BULLISH: Strong technical setup (81/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 23.5% below Wall St target ($395.44)
- NEUTRAL: Market pricing in 4.8% annual earnings growth - fairly valued
- BULLISH: Bottoming setup score 81/100 — corrected, stabilizing, and turning up
Trading Range Analysis
30-Day Trading Range
$323.37 -
$340.21
Current vs Trading Range
OVERSOLD
Expected Move (7 Days)
±$22.06
(6.9%)
Support & Resistance Levels
Support Level
$314.22
Resistance Level
$338.91
Current Trend
Sideways
Technical data as of
Oct 22, 2026
Fundamental Context
Forward P/E (Next Year Est.)
35.76
Wall Street Target
$395.44
(+23.5%)
Revenue Growth (YoY)
24.1%
Earnings Growth (YoY)
38.8%
Profit Margin
54.8%
Valuation Premium vs History
+4.8% premium
PE vs Historical
35.8 vs 31.1
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+4.8%
(market-implied from PE analysis)
1-Year Target
$335.50
(+5%)
2-Year Target
$351.60
(+10%)
3-Year Target
$368.48
(+15%)
3-Yr Target (if PE normalizes)
(PE: 36→31)
PE COMPRESSION
$320.46
(+0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 35.8, Growth: 18.0%)
$525.61
(+64%)
Base:
(SPY PE: 19.9, Growth: 18.0%)
$291.91
(-9%)
Bear:
(PE: 16.9, Growth: 18.0%)
$248.12
(-23%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (40x PE), but valuation improves significantly next year (36x PE) as earnings recover.
Trailing PE: 40.08 | Current EPS (TTM): $7.98
Bull Case
$394.64
(+23%)
Analyst growth 12.2%, PE expands to 44.1
Base Case
$358.77
(+12%)
Market implied 12.2%, PE stable at 40.1
Bear Case
$217.46
(-32%)
Severe decline -20.0%, PE contracts to 34.1
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: October 23, 2026 8:39 AM ET
Data refreshes hourly during market hours. Next update: 9:39 AM
Data refreshes hourly during market hours. Next update: 9:39 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is KRYS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
28 analysts |
$92 | 67 BUY |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
23 analysts |
$108 | 58 HOLD |
|
INCY
Incyte Corporation |
HOLD
28 analysts |
$130 | 77 BUY |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
22 analysts |
$283 | 49 HOLD |
|
MIRM
Mirum Pharmaceuticals Inc |
STRONG BUY
14 analysts |
$153 | 68 BUY |
Advanced KRYS Option Strategies
Professional options setups generated by AI based on today's KRYS price and gamma walls.
